Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 428

1.

A cost-utility analysis of treatment for acute childhood idiopathic thrombocytopenic purpura (ITP).

O'Brien SH, Ritchey AK, Smith KJ.

Pediatr Blood Cancer. 2007 Feb;48(2):173-80.

PMID:
16550529
2.

Canadian cost- utility analysis of intravenous immunoglobulin for acute childhood idiopathic thrombocytopenic purpura.

Blackhouse G, Xie F, Levine MA, Campbell K, Assasi N, Gaebel K, O'Reilly D, Tarride J, Goeree R.

J Popul Ther Clin Pharmacol. 2012;19(2):e166-78. Epub 2012 May 1.

PMID:
22580389
4.

Results of a model analysis to estimate cost utility and value of information for intravenous immunoglobulin in Canadian adults with chronic immune thrombocytopenic purpura.

Xie F, Blackhouse G, Assasi N, Campbell K, Levin M, Bowen J, Tarride JE, Pi D, Goeree R.

Clin Ther. 2009 May;31(5):1082-91; discussion 1066-8. doi: 10.1016/j.clinthera.2009.05.006.

PMID:
19539109
5.
6.

Treatment of childhood acute immune thrombocytopenic purpura with anti-D immune globulin or pooled immune globulin.

Tarantino MD, Madden RM, Fennewald DL, Patel CC, Bertolone SJ.

J Pediatr. 1999 Jan;134(1):21-6.

PMID:
9880444
7.
8.
10.

How far should we go with cost-utility analysis when treating children with acute idiopathic thrombocytopenic purpura?

Benesch M.

Pediatr Blood Cancer. 2008 Feb;50(2):433. No abstract available.

PMID:
17458876
11.

Treatment, outcome, and cost of care in children with idiopathic thrombocytopenic purpura.

Kumar M, Vik TA, Johnson CS, Southwood ME, Croop JM.

Am J Hematol. 2005 Mar;78(3):181-7.

12.

A multicenter study of the treatment of childhood chronic idiopathic thrombocytopenic purpura with anti-D.

Andrew M, Blanchette VS, Adams M, Ali K, Barnard D, Chan KW, DeVeber LB, Esseltine D, Israels S, Korbrinsky N, et al.

J Pediatr. 1992 Apr;120(4 Pt 1):522-7.

PMID:
1313096
13.

A comparative study of initial use of intravenous immunoglobulin and prednisolone treatments in childhood idiopathic thrombocytopenic purpur.

Ou CY, Hsieh KS, Chiou YH, Chang YH, Ger LP.

Acta Paediatr Taiwan. 2006 Sep-Oct;47(5):226-31.

PMID:
17352309
14.

A prospective, randomized trial of high-dose intravenous immune globulin G therapy, oral prednisone therapy, and no therapy in childhood acute immune thrombocytopenic purpura.

Blanchette VS, Luke B, Andrew M, Sommerville-Nielsen S, Barnard D, de Veber B, Gent M.

J Pediatr. 1993 Dec;123(6):989-95.

PMID:
8229536
16.
17.

Childhood acute immune thrombocytopenic purpura: 20 years later.

Blanchette VS, Carcao M.

Semin Thromb Hemost. 2003 Dec;29(6):605-17. Review.

PMID:
14719177
18.

The potential for treatment of idiopathic thrombocytopenic purpura with anti-D to prevent splenectomy: a predictive cost analysis.

Bennett CL, Weinberg PD, Golub RM, Bussel JB.

Semin Hematol. 2000 Jan;37(1 Suppl 1):26-30.

PMID:
10676921
19.

[Intravenous high-dose methylprednisolone efficacy for treatment of idiopathic thrombocytopenic purpura in adults].

Visser R, Zweegman S, Ossenkoppele GJ, Huijgens PC.

Ned Tijdschr Geneeskd. 1999 Oct 9;143(41):2053-7. Dutch.

PMID:
10560547
20.

Supplemental Content

Support Center